Aquablation Therapy for Treatment of Prostate Cancer

Boulder Medical Center Urologists Dr. Stephen Siegel and Dr. Tomy Perez are part of a select group of physicians participating in the WATER IV PCa clinical trial comparing Aquablation® (waterjet) therapy for the treatment of prostate cancer to traditional radical prostatectomy. Boulder Medical Center is one of only 26 locations across the U.S. participating in the study.

The trial is the first of its kind to use the minimally invasive robotically-controlled waterjet surgery to remove cancer tissue compared to traditional surgery that removes the entire prostate.

“Men often try to avoid surgery for prostate cancer due to the concerning side effects of urinary incontinence and erectile dysfunction,” said Dr. Siegel. “This method shows only a 0.1% risk of urinary incontinence and a 0% risk of erectile dysfunction.”

Prostate cancer is among the most diagnosed cancers in men. According to the American Cancer Society, about one in every eight men will be diagnosed with prostate cancer in their lifetime and there are more than 299,010 new cases of prostate cancer diagnosed in the U.S. each year, resulting in about 35,250 deaths.

“The results of this study could be life-changing for men diagnosed with prostate cancer,” said Dr. Perez.

Biological males with grade group 1-3 localized prostate cancer may be a candidate for the study.

Men interested in being part of the study can ask for a referral from their primary care provider or contact Urology at Boulder Medical Center directly at 303-440-3093 for an appointment.